SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3733-3737. Prepublished online as a Blood First Edition Paper on December 22, 2005; DOI 10.1182/blood-2005-07-2933. This Article Full Text (PDF) All Versions of this Article: 2005-07-2933v1 107/9/3733    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Borgna-Pignatti, C. Articles by Cnaan, A. Search for Related Content PubMed PubMed Citation Articles by Borgna-Pignatti, C. Articles by Cnaan, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 21, 2005 Accepted November 28, 2005 Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major Caterina Borgna-Pignatti*, Maria Domenica Cappellini, Piero De Stefano, Giovanni Carlo Del Vecchio, Gian Luca Forni, Maria Rita Gamberini, Roberta Ghilardi, Antonio Piga, Maria Antonietta Romeo, Huaqing Zhao, and Avital Cnaan Clinica Pediatrica, University of Ferrara, Ferrara, Italy Centro Anemie Congenite, Ospedale Maggiore Policlinico, IRCCS, Milano, Italy Oncoematologia Pediatrica, IRCCS Policlinico San Matteo, Pavia, Italy Clinica Pediatrica, University of Bari, Bari, Italy Centro Microcitemie, Ospedali Galliera, Genova, Italy Divisione Pediatrica, Arcispedale Sant'Anna, Ferrara, Italy Clinica Pediatrica I, University of Milano, Milano, Italy Centro Microcitemie, University of Torino, Torino, Italy Clinica Pediatrica, University of Catania, Catania, Italy Division of Biostatistics and Epidemiology at The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, USA * Corresponding author; email: c.borgna{at}unife.it. Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995 the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995 to December 31, 2003. All patients with thalassemia major, treated in seven Italian centers, born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients and 157 patients received deferiprone for part of the time. A total of 3610 patient years were observed on DFO and 750 on deferiprone. At baseline, the two groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least eighteen months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Vichinsky Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia Pediatrics, June 1, 2008; 121(6): 1253 - 1256. [Full Text] [PDF] W.-Y. Au, W. W.-m. Lam, W. W.C. Chu, H.-L. Yuen, A. S.-C. Ling, R. C.-H. Li, H. M.-H. Chan, H. K.-K. Lee, M.-F. Law, H. S. Y. Liu, et al. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong Haematologica, May 1, 2008; 93(5): 784 - 786. [Full Text] [PDF] E. Angelucci, G. Barosi, C. Camaschella, M. D. Cappellini, M. Cazzola, R. Galanello, M. Marchetti, A. Piga, and S. Tura Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders Haematologica, May 1, 2008; 93(5): 741 - 752. [Abstract] [Full Text] [PDF] S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah The Role of Iron in Diabetes and Its Complications Diabetes Care, July 1, 2007; 30(7): 1926 - 1933. [Full Text] [PDF] N. Boddaert, K. H. Le Quan Sang, A. Rotig, A. Leroy-Willig, S. Gallet, F. Brunelle, D. Sidi, J.-C. Thalabard, A. Munnich, and Z. I. Cabantchik Selective iron chelation in Friedreich ataxia: biologic and clinical implications Blood, July 1, 2007; 110(1): 401 - 408. [Abstract] [Full Text] [PDF] M.A. Tanner, R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Circulation, April 10, 2007; 115(14): 1876 - 1884. [Abstract] [Full Text] [PDF] J. L. Stumpf Deferasirox Am. J. Health Syst. Pharm., March 15, 2007; 64(6): 606 - 616. [Abstract] [Full Text] [PDF] G. Fabio, F. Minonzio, P. Delbini, A. Bianchi, and M. D. Cappellini Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH) Blood, January 1, 2007; 109(1): 362 - 364. [Abstract] [Full Text] [PDF] H. Glickstein, R. B. El, G. Link, W. Breuer, A. M. Konijn, C. Hershko, H. Nick, and Z. I. Cabantchik Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences Blood, November 1, 2006; 108(9): 3195 - 3203. [Abstract] [Full Text] [PDF] A. R. Cohen New Advances in Iron Chelation Therapy Hematology, January 1, 2006; 2006(1): 42 - 47. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020